Ascendis Pharma A/S holding history
As of Nov. 6, 2026 (UTC)
| March 31, 2025 | 4,256,627 | $663,437,884 | 1.07% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 14, 2025 |
| June 30, 2025 | 3,990,424 | $688,747,182 | 1.01% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 12, 2025 |
| Sept. 30, 2025 | 3,720,880 | $739,748,153 | 1.05% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Nov. 12, 2025 |
| Dec. 31, 2025 | 3,225,885 | $687,887,701 | 1.03% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Feb. 17, 2026 |
| March 31, 2026 | 3,230,188 | $738,840,836 | 1.19% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 13, 2026 |
| June 30, 2026 | Absent this quarter | — | — | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 13, 2026 |
6 rows · Sort by column; scroll horizontally for more.
No rows match these filters.
Schedule 13G disclosures
No verified related disclosures are included in this freeze.
About reported holdings
13F reports quarter-end securities, excluding cash and shorts. Position changes do not establish trades, motives or returns; portfolio weights use disclosed 13F value.